Net loss of 16.9B, accumulated deficit of 95B, going concern uncertainty, asset sale and new business push
- FY2025 consolidated revenue 2.85B, operating loss 8.38B, net loss 16.94B, accumulated deficit 95.04B. Basic EPS loss 722 won.
- Going concern uncertainty exists. Mitigation plans include real estate sale (expected ~30B inflow) and perpetual convertible bond issuance (35.6B).
- On Dec 31, 2025, issued 35.6B perpetual convertible bonds to (Yoo) Human Data (classified as capital surplus).
- Subsequent events: borrowing 5B from related party in Jan 2026, and 3.21B paid-in capital increase via third-party allotment to (Yoo) Realitygen in Mar 2026.
- Articles amended: authorized shares from 100M to 300M, CB/BW issuance limit from 100B to 400B each, business purpose expanded to include data center, AI, etc.
- No dividends. Director compensation cap 1.2B, auditor compensation cap 200M.
- All 5 inside directors re-elected (Kang Seong-min, Jeon Yong-beom, Yoo Se-kwon, Yoo Se-young, Park Tae-ho). Yoo Se-kwon's entity participated in CB purchase and capital increase.
ADVERTISEMENT (250px+)
KOSDAQ Filing Information
- Filing: Proxy Statement
- Company: PeopleBio (304840)
- Submission: PeopleBio, Inc.
- Receipt: 04-27-2026